Neurocrine Biosciences, Inc. (NBIX) Q4 2014 Earnings Results

Neurocrine Biosciences Misses on EPS — Stock Down 1.03%

The earnings report indicates that Neurocrine Biosciences is facing challenges, as reflected in their EPS miss. The stock's slight decline of 1.03% suggests that investors are reacting cautiously to the company's performance. Without updated guidance, uncertainty remains about the company's short-term outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.26	N/A	-10.64%

Management

Management commentary

Tone: Defensive

Overall, management expressed concern over recent performance but remains focused on future opportunities. They did not provide specific guidance for upcoming quarters.

Management acknowledged challenges in meeting expectations this quarter.

They emphasized a focus on long-term growth despite current setbacks.

Neurocrine Biosciences Misses on EPS — Stock Down 1.03%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS — Stock Down 1.03%

Key numbers

Management commentary